These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28118649)

  • 1. Lixisenatide for type 2 diabetes.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):19-21. PubMed ID: 28118649
    [No Abstract]   [Full Text] [Related]  

  • 2. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Tsutsumi Y; Tsujimoto Y; Ikenoue T
    N Engl J Med; 2016 Mar; 374(11):1094-5. PubMed ID: 26981946
    [No Abstract]   [Full Text] [Related]  

  • 3. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Pfeffer MA; Claggett B; Probstfield JL
    N Engl J Med; 2016 Mar; 374(11):1095-6. PubMed ID: 26981945
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes: Lixisenatide does not increase rates of CVD events.
    Huynh K
    Nat Rev Cardiol; 2016 Feb; 13(2):63. PubMed ID: 26701217
    [No Abstract]   [Full Text] [Related]  

  • 5. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
    Christensen M; Knop FK; Holst JJ; Vilsboll T
    IDrugs; 2009 Aug; 12(8):503-13. PubMed ID: 19629885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Salvador J; Gaztambide S
    Med Clin (Barc); 2014; 143 Suppl 2():1. PubMed ID: 25326835
    [No Abstract]   [Full Text] [Related]  

  • 7. New Injectable Drug for Type 2 Diabetes.
    Aschenbrenner DS
    Am J Nurs; 2016 Nov; 116(11):22-23. PubMed ID: 27787319
    [No Abstract]   [Full Text] [Related]  

  • 8. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
    Hanefeld M; Raccah D; Monnier L
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.
    Forst T
    Expert Opin Pharmacother; 2016 Aug; 17(12):1703-8. PubMed ID: 27341040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Derosa G; Maffioli P
    N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus.
    Forst T; Pfützner A
    Expert Opin Pharmacother; 2013 Nov; 14(16):2281-96. PubMed ID: 24087882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lixisenatide for type 2 diabetes mellitus.
    Christensen M; Knop FK; Vilsbøll T; Holst JJ
    Expert Opin Investig Drugs; 2011 Apr; 20(4):549-57. PubMed ID: 21391833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer GLP-1 receptor agonists and obesity-diabetes.
    Brown E; Cuthbertson DJ; Wilding JP
    Peptides; 2018 Feb; 100():61-67. PubMed ID: 29412833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors).
    Nunez DJ; D'Alessio D
    Diabetes Obes Metab; 2018 Feb; 20(2):233-237. PubMed ID: 28842950
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of lixisenatide in elderly (≥65 years old) and very elderly (≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme.
    Raccah D; Miossec P; Esposito V; Niemoeller E; Cho M; Gerich J
    Diabetes Metab Res Rev; 2015 Feb; 31(2):204-11. PubMed ID: 25115916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
    Geurin MD
    Am Fam Physician; 2016 Mar; 93(6):436-8. PubMed ID: 26977827
    [No Abstract]   [Full Text] [Related]  

  • 18. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
    Morano S; Romagnoli E; Filardi T; Nieddu L; Mandosi E; Fallarino M; Turinese I; Dagostino MP; Lenzi A; Carnevale V
    Acta Diabetol; 2015 Aug; 52(4):727-32. PubMed ID: 25577244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus.
    Bae JH; Choi HJ; Cho KIK; Kim LK; Kwon JS; Cho YM
    Diabetes Metab J; 2020 Apr; 44(2):248-259. PubMed ID: 31701698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in peptide-based therapy for Type 2 diabetes and obesity.
    Conlon JM; Flatt PR; Bailey CJ
    Peptides; 2021 Nov; 145():170652. PubMed ID: 34555424
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.